BMI-2004 (A Recombinant Hyaluronidase): Advancing Subcutaneous Drug Delivery - Phase 1 Clinical Trial Results to Be Presented at the 15th Annual Bioprocessing Summit in Boston

Dr. Hojoon Choi, Executive Vice President and Chief Strategy Officer of the company will present a podium talk titled "BMI-2004: A Breakthrough in Subcutaneous Drug Delivery" on August 16th. The presentation highlights BMI-2004's potential in enhancing patient experience and treatment outcomes where Dr. Choi will share the results from Phase 1 clinical trial of BMI-2004. "BMI-2004 demonstrated a favorable safety profile with a very low incidence of injection site reactions" said Dr. Choi. Dr...

Dr. Hojoon Choi, Executive Vice President and Chief Strategy Officer of the company will present a podium talk titled "BMI-2004: A Breakthrough in Subcutaneous Drug Delivery" on August 16th. The presentation highlights BMI-2004's potential in enhancing patient experience and treatment outcomes where Dr. Choi will share the results from Phase 1 clinical trial of BMI-2004. "BMI-2004 demonstrated a favorable safety profile with a very low incidence of injection site reactions" said Dr. Choi.

The trial, with 250 healthy participants, evaluated BMI-2004's safety and tolerability (ClinicalTrials.gov: NCT05922813). Dr. Prof. Beom Joon Kim, MD, Ph.D. from Chung-Ang University Hospital led the trial as the principal investigator.

BMI Korea seeks strategic partnerships for co-formulation development to transition from IV to SC biologics, leveraging BMI-2004 hyaluronidase and liquid formulation technology. Join BMI Korea's presentation and visit BMI Korea's booth (#110) at the conference to explore the latest developments.

About BMI Korea Co., LTD.
BMI Korea is a leading South Korean biotech company dedicated to advancing biologics, pharmaceuticals, and medical devices. We are committed to transforming healthcare and addressing unmet medical needs worldwide through innovation and patient-centric solutions.
BMI KOREA (bmikr.co.kr)

Contacts
BMI Korea Co., LTD.
Kacy Kim, Director
Business Development
bumeun.kim@bmikr.co.kr

View original content:https://www.prnewswire.co.uk/news-releases/bmi-2004-a-recombinant-hyaluronidase-advancing-subcutaneous-drug-delivery---phase-1-clinical-trial-results-to-be-presented-at-the-15th-annual-bioprocessing-summit-in-boston-301898168.html